Last updated: April 28, 2026
Who Supplies Carglumic Acid to the Market?
What manufacturing and sourcing patterns exist for carglumic acid?
Carglumic acid is an established, small-molecule therapy used for hyperammonemia due to NAGS deficiency (and in some settings hyperammonemia associated with other inherited urea-cycle disorders). In practical procurement terms, “suppliers” split into two groups:
- Marketing-authorisation holders and branded-generic commercial suppliers selling finished medicine under national/regional labels (product-level supply).
- API and intermediate supply chains feeding formulators and finished-dose manufacturers (API-level supply).
Carglumic acid’s supply chain is concentrated: only a small number of producers support global demand, and many regional suppliers operate as commercial packers/distributors rather than original API manufacturers.
Which companies supply carglumic acid (product and API) in practice?
Below are the recurring, commercially relevant suppliers visible across regulatory filings and market availability for carglumic acid-based finished products and commercial API sourcing.
| Supplier type |
Company |
What they supply |
Evidence basis |
| Finished-dose commercial supplier |
Recordati Rare Diseases |
Branded carglumic acid (in many EU markets through national authorizations) |
Product/regulatory presence and distribution through national labels (see cited product information) |
| Finished-dose commercial supplier |
Advanz Pharma |
Branded carglumic acid products in some markets where the company holds commercialization rights |
Market presence via authorization and product literature (see cited product information) |
| Finished-dose commercial supplier |
Actavis / Teva network (via regional labels) |
Generic or authorized supply of carglumic acid in select jurisdictions |
Regulatory and market authorizations supporting alternative branding (see cited product information) |
| API supply chain |
Aarti / other specialty API manufacturers (varies by region) |
Carglumic acid API for downstream formulation |
API availability and licensing patterns reflected in regulatory and commercial listings (see cited sources) |
| API supply chain |
F. Hoffmann-La Roche affiliate network (historical/legacy procurement patterns) |
Legacy sourcing participation for certain rare-disease products |
Historic commercialization footprint for urea-cycle disorder products (see cited regulatory/product sources) |
Note on market behavior: finished-dose distributors frequently change by country and tender cycle. API availability also varies by qualification status (DMF/ASMF acceptance, GMP certificates, and importer qualification). The companies above represent the recurring commercial footprints seen across major markets; exact “who supplies your tender” is typically defined at the national product-authorisation and distributor level rather than at a global vendor list.
Which branded and generic entries anchor the supplier landscape?
Carglumic acid market visibility is highest where product branding and regulatory dossiers are stable. The most cited anchor products include:
- Carbaglu (carglumic acid) as the reference branded product in multiple regions under the Recordati footprint (see cited product information).
- Regionally branded authorized generic or branded generic carglumic acid tablets/suspensions sold under different labels depending on jurisdiction and tender history (see cited regulatory product information for example entries).
This matters for supply chain due diligence: if a national tender requires the reference product, your supplier list maps to the brand owner and its logistics partners. If the tender accepts equivalents, supplier lists expand to authorized generics and their packers.
How to translate “supplier” into a procurement-ready list (API vs finished product)?
Procurement teams typically need two parallel supplier views:
1) Finished-dose suppliers (market-facing)
Use this for pharmacy distribution, hospital tenders, and country-level purchase orders.
- Brand owner commercial route: Recordati Rare Diseases
- Alternative commercialization routes: Advanz Pharma and regional generic/commercial partners under national authorizations
- Country-by-country packers/distributors: often appear on local product leaflets and tender catalogs, even when they do not manufacture
2) API suppliers (upstream, qualification-gated)
Use this for formulators, contract manufacturers, and pipeline projects that require API availability and regulatory completeness.
- API sourcing is commonly gated by:
- DMF/ASMF acceptance status in target markets
- CEP/GMP compliance for the specific API site
- Ability to meet batch release testing and impurity specs consistent with the finished-dose monograph/label
What supplier due-diligence items matter most for carglumic acid?
Carglumic acid supplier qualification tends to be strict because rare-disease supply failures create immediate continuity risk. The core due-diligence checklist for API or finished dose includes:
- GMP compliance at the API or finished-dose site (inspection status and last inspection date)
- Regulatory dossier alignment (DMF/ASMF referenced in finished-dose submissions in your target regions)
- Batch release testing package covering:
- identity
- assay
- specified impurities and residual solvents (where applicable)
- particle size and stability-related parameters if relevant to dosage form
- Cold chain or special handling requirements (if any) for the specific finished-dose presentation in your jurisdiction
- Supply continuity (multi-site supply options and change control history)
How concentrated is the supply chain?
The carglumic acid market is small but high-stakes. Demand is clinically fixed and pricing is regulated in many jurisdictions, which leads to:
- Limited upstream competition at the API level
- Multiple downstream labels for finished-dose marketing depending on country licensing and tender outcomes
- Supplier qualification cycles that can lag market entry by months to years, even when API is technically producible
What are the practical supplier-relevant milestones to monitor?
For business teams tracking supplier risk and onboarding new sources, monitor these milestones:
- Regulatory updates to national product leaflets (product availability and manufacturer of record changes)
- Variation approvals that indicate manufacturing site transfers or changes to the manufacturing process
- Re-registrations and renewals for national authorizations (which often trigger refresh of the supplier list used by distributors)
- GMP inspection outcomes for API sites used for current commercial lots
Key Takeaways
- Carglumic acid sourcing splits into finished-dose commercialization suppliers and API upstream suppliers; due diligence should reflect which procurement path you are using.
- Recordati Rare Diseases is the primary recurring commercial supplier footprint via Carbaglu in major markets.
- Advanz Pharma and regional generic/authorized partners appear as additional finished-dose commercial suppliers depending on jurisdiction and tender rules.
- API sourcing is highly qualification-gated, so supplier lists for API change less frequently than finished-dose labels, but carry the highest risk if a site loses approval or inspection standing.
- Procurement teams should anchor supplier decisions to national product authorizations and documented GMP/regulatory dossier linkage rather than global “availability” claims.
FAQs
1) Are carglumic acid suppliers the same worldwide?
No. Finished-dose suppliers vary by country due to authorization holders, distributors, and tender contracts. API suppliers also vary based on qualified sites in each regulatory region.
2) Who typically supplies the branded reference product?
The branded reference product footprint for carglumic acid is anchored by Recordati Rare Diseases in multiple markets under Carbaglu.
3) Can a generic tender accept any carglumic acid API supplier?
No. Many generics require API that matches specific dossier references and impurity/spec profiles accepted by regulators. Qualification status and change-control history matter.
4) What is the main risk in carglumic acid supply?
Continuity risk tied to a small number of qualified upstream sites and a limited number of finished-dose commercial partners per jurisdiction.
5) What should be checked first when onboarding a new supplier?
GMP status for the specific manufacturing site and alignment with the regulatory dossier (DMF/ASMF linkage) for the target markets.
References
[1] Recordati Rare Diseases. Carbaglu (carglumic acid) product information and summary documentation.
[2] European Medicines Agency. Public assessment reports and related documents for carglumic acid-containing products.
[3] Advanz Pharma. Carglumic acid product documentation and commercialization materials (where applicable by region).
[4] Teva/Actavis. Authorized generics or national product information for carglumic acid (jurisdiction-dependent).
[5] US FDA. Drug applications and regulatory references relevant to carglumic acid products (public sources).
